Market closed
AC Immune/$ACIU
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About AC Immune
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Ticker
$ACIU
Sector
Trading on
Industry
Biotechnology
Headquarters
Lausanne, Switzerland
Employees
147
Website
AC Immune Metrics
BasicAdvanced
$291M
Market cap
-
P/E ratio
-$0.76
EPS
1.27
Beta
-
Dividend rate
Price and volume
Market cap
$291M
Beta
1.27
52-week high
$5.14
52-week low
$2.25
Average daily volume
80K
Financial strength
Current ratio
1.796
Quick ratio
1.757
Long term debt to equity
2.06
Total debt to equity
2.616
Interest coverage (TTM)
-492.10%
Management effectiveness
Return on assets (TTM)
-19.06%
Return on equity (TTM)
-46.06%
Valuation
Price to revenue (TTM)
15.194
Price to book
2.37
Price to tangible book (TTM)
4.01
Price to free cash flow (TTM)
5.373
Growth
Revenue change (TTM)
293.60%
Earnings per share change (TTM)
-17.96%
3-year revenue growth (CAGR)
95.71%
3-year earnings per share growth (CAGR)
-14.12%
What the Analysts think about AC Immune
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AC Immune stock.
AC Immune Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AC Immune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AC Immune stock?
AC Immune (ACIU) has a market cap of $291M as of December 14, 2024.
What is the P/E ratio for AC Immune stock?
The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of December 14, 2024.
Does AC Immune stock pay dividends?
No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next AC Immune dividend payment date?
AC Immune (ACIU) stock does not pay dividends to its shareholders.
What is the beta indicator for AC Immune?
AC Immune (ACIU) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.